Eric Daniels
Corporate Officer/Principal at KIORA PHARMACEUTICALS, INC.
Net worth: 614 $ as of 2024-05-30
Eric Daniels active positions
| Companies | Position | Start | End |
|---|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-10-20 | - |
Okogen, Inc.
 Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Director/Board Member | - | - |
| Founder | - | - | |
| Bayon Therapeutics, Inc. | Director/Board Member | - | - |
| Founder | - | - |
Career history of Eric Daniels
Former positions of Eric Daniels
| Companies | Position | Start | End |
|---|---|---|---|
OccuRx Pty Ltd
 OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Chief Executive Officer | - | - |
Training of Eric Daniels
| University of California, Berkeley | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
| Anderson School of Management | Masters Business Admin |
Statistics
International
| United States | 7 |
| Australia | 2 |
Operational
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Okogen, Inc.
Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |
OccuRx Pty Ltd
OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
| Bayon Therapeutics, Inc. |
- Stock Market
- Insiders
- Eric Daniels
- Experience
